Stryker CEO Kevin Lobo says robots now do 2 of every 3 knee replacements—and he won’t build them in China because ‘the IP is a massive worry’
Kevin Lobo told Fortune that Chinese companies are “knocking off a lot of the other robots” as Stryker bets $400 million on a soft-tissue surgical robot.
Stryker's CEO Kevin Lobo claims that robots now perform two out of every three knee replacement surgeries, utilizing the company's Mako system. Lobo asserts that Stryker has no plans to produce these robots in China, citing intellectual property concerns. The Mako system, which has been used in 2.5 million procedures across 47 countries, has made robots a crucial selling point for Stryker.
Meanwhile, Chinese firms like MicroPort MedBot, which manufactures a soft-tissue surgical robot named Toumai, have rapidly expanded, securing over 300 global orders and installations in more than 60 countries. Lobo's competitor has reportedly invested in a Chinese robotics company. Stryker is exploring the possibility of Chinese firms creating new robots for other areas of the body but believes clinical expertise is crucial for success in this field.
The company is also investing in soft-tissue robotics, making a $400 million equity investment in CMR Surgical, a London-based firm that develops less expensive alternatives to Intuitive Surgical's high-priced robots. Stryker aims to be the exclusive U.S. sales agent for CMR's Versius soft-tissue robot and could potentially acquire the company.
Written by urgent.news from Fortune's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.